US Tablet Press Exterior Cleaning: Trial and Release Checks

Can a US drug manufacturer trial dry ice blasting on a tablet press exterior?

A US drug manufacturer can assess dry ice blasting on a stopped tablet press’s accessible nonproduct-contact exterior, but the trial must remain outside its validated product-contact cleaning process. The site must control dust migration, isolate hazardous energy, protect tooling and open product paths, and document inspection before the press returns to service.

This article concerns an exterior frame, guard or hinge in a controlled maintenance window. It does not establish that dry ice blasting is suitable for punches, dies, hoppers or any surface that contacts a drug product. The FDA’s equipment cGMP Q&A points to written procedures and records under 21 CFR 211.67 for cleaning and maintenance. The site’s quality unit determines whether and how a proposed method fits those procedures.

Where should the first trial stop?

Choose one small outer frame or removable nonproduct-contact guard with representative buildup. Map the boundary on a maintenance photograph. Identify seals, wiring, bearings, sensors, openings into the product path and any finish that could be damaged. Remove or protect product-contact tooling under the site’s established procedure. Nozzle direction and temporary shielding should keep detached powder from moving toward clean equipment, open containers or adjacent production.

The trial plan should state what happens to displaced powder. Sublimation of the dry ice media does not remove the soil from the room. Use site-approved capture and housekeeping methods, and account for the particle size and potency of the particular material; do not make a generic exposure claim. A DryIceSys site-readiness checklist can help organize air, access and containment questions, but it does not replace the manufacturer’s contamination-control assessment.

What evidence is needed before a wider roll-out?

Record the press model, exterior material, soil identity, test location, operator, nozzle setup, air supply, exposure time and observed effect. Inspect for coating damage, fastener loosening, residue trapped behind guards and migration into excluded areas. If the proposed operation touches product-contact surfaces, it becomes a separate qualification question. The FDA inspection guide on validation of cleaning processes explains why residue limits, sampling and evidence for the actual process matter; a photograph of a clean-looking surface is not validation.

How should maintenance control the work area?

Follow the facility’s energy-control procedure before opening guards or entering a pinch-point area. OSHA’s control-of-hazardous-energy standard is the US regulatory reference for servicing and maintenance lockout. Assess compressed air, noise, potential airborne powder and local ventilation. Carbon dioxide can accumulate in inadequately ventilated areas; the NIOSH carbon-dioxide entry supplies exposure and hazard information for the risk assessment.

For equipment selection, measure actual compressor delivery and compare it with the DryIceSys air-requirements guide. Trial one representative finish before specifying a machine for multiple tablet-press models. Write a stop criterion for coating damage or dust migration.

What is the release decision?

The maintenance record should show that the defined exterior deposit was treated, excluded areas remained protected, displaced material was captured, guards and interlocks were restored, and the site’s approved cleaning and quality checks were completed. The quality unit retains authority over any cGMP impact. A purchase case should compare the trial’s measured labor, access and containment demands with the current method; the DryIceSys cost guide is only a budgeting starting point. This is a limited exterior-maintenance decision, not a blanket endorsement for pharmaceutical product-contact cleaning.

Images are AI-generated editorial illustrations, not a customer site or evidence of regulatory validation.